Gsk (GLAXF) Cash & Current Investments (2009 - 2026)

Gsk's Cash & Current Investments history runs 18 years deep, the most recent figure standing at $4.4 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 23.69% year-over-year to $4.4 billion; the TTM figure through Mar 2026 stood at $4.4 billion (down 23.69% YoY), while the FY2025 annual figure was $4.6 billion, down 8.8% from the prior year.
• Cash & Current Investments was $4.4 billion for Q1 2026 at Gsk, down from $4.7 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $14.7 billion in Q1 2022 to a low of $3.5 billion in Q1 2024.
• Historically, Cash & Current Investments has averaged $5.6 billion across 5 years, with a median of $4.5 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments jumped 113.42% in 2022, then plunged 75.05% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $9.2 billion in 2022, then tumbled by 30.36% to $6.4 billion in 2023, then retreated by 19.95% to $5.1 billion in 2024, then dropped by 8.37% to $4.7 billion in 2025, then retreated by 6.37% to $4.4 billion in 2026.
• The last three Cash & Current Investments figures came in at $4.4 billion (Q1 2026), $4.7 billion (Q4 2025), and $4.3 billion (Q3 2025), per Business Quant data.